AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
1.100
+0.035 (3.29%)
At close: Dec 5, 2025, 4:00 PM EST
1.080
-0.020 (-1.82%)
After-hours: Dec 5, 2025, 7:29 PM EST
AN2 Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Net Income | -33.99 | -51.32 | -64.73 | -40.96 | -21.54 | -13.6 | |
| Asset Writedown & Restructuring Costs | - | - | - | - | - | 0.65 | |
| Loss (Gain) From Sale of Investments | -1.52 | -3.28 | -2.86 | -0.69 | 0.05 | - | |
| Stock-Based Compensation | 6.63 | 8.34 | 8.41 | 4.39 | 0.97 | 0.04 | |
| Other Operating Activities | - | - | 0.05 | 0.08 | - | 6.32 | |
| Change in Accounts Payable | 0.52 | 0.64 | 0.55 | 2.5 | 0.42 | 0.08 | |
| Change in Other Net Operating Assets | -1.51 | -3.64 | 5.28 | 1.22 | -0.39 | 1.14 | |
| Operating Cash Flow | -29.87 | -49.26 | -53.29 | -33.46 | -20.48 | -5.36 | |
| Investment in Securities | 14.26 | 54.59 | -43.28 | -21.77 | -50.02 | - | |
| Investing Cash Flow | 14.26 | 54.59 | -43.28 | -21.77 | -50.02 | - | |
| Issuance of Common Stock | 0.11 | 0.37 | 84.99 | 70.37 | 0.01 | 0.06 | |
| Repurchase of Common Stock | - | - | - | -0.01 | - | - | |
| Other Financing Activities | - | - | - | - | -1.21 | - | |
| Financing Cash Flow | 0.11 | 0.37 | 84.99 | 70.36 | 78.54 | 3.84 | |
| Net Cash Flow | -15.5 | 5.7 | -11.57 | 15.12 | 8.03 | -1.53 | |
| Levered Free Cash Flow | -17.74 | -29 | -28.85 | -19.3 | -11.96 | -3.27 | |
| Unlevered Free Cash Flow | -17.74 | -29 | -28.85 | -19.3 | -11.96 | -3.27 | |
| Change in Working Capital | -0.99 | -3 | 5.83 | 3.72 | 0.03 | 1.22 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.